Journal
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
Volume 1780, Issue 2, Pages 75-88Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbagen.2007.11.003
Keywords
anti-gal; alpha-1,3galactosyltransferase; alpha-gal epitopes; xenotransplantation; cancer immunotherapy; cancer vaccine; viral vaccine
Categories
Funding
- NCI NIH HHS [R01CA85868] Funding Source: Medline
- NIAID NIH HHS [R21AI58749, R21 AI058749] Funding Source: Medline
- NIGMS NIH HHS [R01 GM040205-11, R01GM040205] Funding Source: Medline
Ask authors/readers for more resources
In 1985, we reported that a naturally occurring human antibody (anti-Gal), produced as the most abundant antibody (1% of immunoglobulins) throughout the life of all individuals, recognizes a carbohydrate epitope Gal alpha 1-3Gal beta 1-4GlcNAc-R (the alpha-gal epitope). Since that time, an extensive literature has developed on discoveries related to the alpha-gal epitope and the anti-Gal antibody, including the barrier they form in xenotransplantation and their reciprocity in mammalian evolution. This review covers these topics and new avenues of clinical importance related to this unique antigen/antibody system (alpha-gal epitope/anti-Gal) in improving the efficacy of viral vaccines and in immunotherapy against cancer. (C) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available